Zahra Eydizadeh

Zahra Eydizadeh

Auto-generated profile, based on publicly available information

Zahra Eydizadeh

Department of Operating Room Nursing, Mother and Child Welfare Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2024 in Journal of Preventive Epidemiology
Verified
Journal Article
Open access
BTBanafsheh Tehranineshat
Banafsheh Tehranineshat
NSNasim Zaman Samghabadi
Nasim Zaman Samghabadi
ZSZahra Shahryarpanah
Zahra Shahryarpanah
ZEZahra Eydizadeh
Zahra Eydizadeh
RJRoya Raeisi Jaski
Roya Raeisi Jaski
NPNajmeh Parsai
Najmeh Parsai
Introduction: Surgery cancellation causes complications such as disrupting the daily schedule of surgery in the operating room, delays in patient care, and potential financial losses for the hospital or surgical center. Objectives: This study aimed to investigate the prevalence and causes of gynecological surgery cancellations at Shariati Bandar Abbas hospital. Patients and Methods: This descriptive-analytical study was conducted on 212 patients in the Shariati hospital of Bandar Abbas, Iran, from April to November 2023. Data were collected through a demographic questionnaire and a researcher-made checklist, including clinical data. To analyze data SPSS version 27 and analytical tests were used. Results: Out of 212 studied patients, the surgery for 67 was canceled, resulting in a surgery canceling prevalence rate of 31.6%. Surgery type, age, history of diabetes mellitus, thyroid disease, and other diseases were not risk factors for surgery cancelation (P>0.05); however, cardiovascular disease history, not being nil per os (NPO), and not having surgery consent were independent risk factors (P<0.05). Conclusion: In conclusion, the high prevalence of surgery cancellations in Iran’s educational hospitals necessitates a comprehensive and systematic investigation of the factors involved, including patient evaluation, anesthesiologist approval, patient readiness, and the impact on patients’ overall health and well-being.

9 November 2025 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
Sina Salem AhimSina Salem Ahim
Sina Salem Ahim
RAR.J. Arismani
R.J. Arismani
MMM. Miri
M. Miri
SKS.G. Kermani
S.G. Kermani
MNM.S.Q. Nou
M.S.Q. Nou
MSM. Safari
M. Safari
Introduction: Kidney transplantation is a critical treatment for end-stage kidney disease, but its costs vary widely across countries and over time. Objectives: This study investigates changes in kidney transplantation costs between 2019 and 2023 using data from the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA). Methods: This ecological study analyzed kidney transplantation costs reported globally for 2019 and 2023 using data from the ISN-GKHA. The study included countries with complete cost data for both years, excluding those with missing or inconsistent records. Data collection focused on extracting first-year and subsequent annual transplantation costs from the publicly available ISN database. The primary outcome was the change in transplantation costs over time, evaluated to identify trends and regional variations in expenses across the included countries. Results: The trend from 2019 to 2023 in kidney transplantation costs varies by continent and globally. In Latin America, Brazil showed the highest increase, while Bolivia had the smallest. Oceania and Southeast Asia saw Australia with the largest increase and Indonesia with a decrease. Western Europe had the Netherlands with the greatest rise and Germany with a decrease. Saudi Arabia had the highest increase in the Middle East, while the West Bank and Gaza had the least. South Asia’s Bangladesh showed a modest increase. In North America, the United States experienced the largest increase, whereas Canada had a decrease. North and East Asia saw Japan with the most notable increase and China with a decrease. Africa had Morocco with the highest increase and Egypt with the smallest. Eastern and Central Europe recorded the largest rise in Slovenia and the smallest in Serbia. Overall, the United States had the most significant increase, while Germany showed the greatest decrease. Conclusion: The findings highlight significant regional disparities in kidney transplantation costs globally, emphasizing the necessity for targeted healthcare policies and ongoing monitoring to ensure cost-effective and equitable access to transplantation services worldwide.

14 August 2026 in International Journal of Medical Informatics
Verified
Journal Article
Closed access
FMFarzaneh Nekuei Manesh
Farzaneh Nekuei Manesh
ZEZahra Eydizadeh
Zahra Eydizadeh
MSMohammad Reza Sohrabi
Mohammad Reza Sohrabi
LALeila Akbari
Leila Akbari
MJMina Jouzi
Mina Jouzi
FSFarkhondeh Sameipoor
Farkhondeh Sameipoor

28 March 2026 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
NNNaeem Nikpour
Naeem Nikpour
RFReza Farzaneh
Reza Farzaneh
MDMohammad Mehdi Darzi
Mohammad Mehdi Darzi
SZSimin Zeinadini
Simin Zeinadini
SSSetare Sadeghi
Setare Sadeghi
RARasoul Jafari Arismani
Rasoul Jafari Arismani
Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs like 177Lu-DOTATATE) is highly effective for metastatic neuroendocrine tumors (NETs). However, a significant dose-limiting toxicity is radiation-induced nephropathy, primarily driven by a phenomenon termed the proximal tubular trap. Following glomerular filtration, radiolabeled peptides are avidly reabsorbed by proximal tubular epithelial cells (PTECs) via the megalin/cubilin receptor-mediated endocytosis pathway. This intracellular retention concentrates the radionuclide within the tubules, leading to prolonged, localized irradiation of renal tissue, particularly the radiosensitive proximal tubules and microvasculature. Cumulative radiation exposure causes DNA damage, oxidative stress, inflammation, and ultimately progressive tubular atrophy, interstitial fibrosis, and glomerulosclerosis, manifesting clinically as declining glomerular filtration rate (GFR), proteinuria, and potentially end-stage renal disease months to several years post-therapy.